Expiration date: 05/2026

Composition

Vinpocetine concentrate for the preparation of infusion solution is a transparent slightly colored liquid.

active substance: Vinpocetine 5 mg / ml 

excipients: propylene glycol, citric acid, sorbitol, sodium disulfite, sodium sulfite, edetate dinatria, hydrochloric acid, water for injection, 

on 2 or 5 ml in ampoules from light-protective glass, on 10 ampoules in packing.

Pharmacological action:

Vinpocetine has vasodilating, anti-hypoxic and effect action. Inhibits phosphodiesterase and increases the content of cyclic adenosine monophosphate in cells, which in turn leads to a decrease in calcium content in the cytoplasm of smooth muscle cells and relaxation of myofibrils. A combination of vascular and metabolic effect. Dilates brain vessels, increases blood flow, mainly in ischemic areas, improves the supply of oxygen to the brain. Promotes glucose utilization and increases the level of catecholamines in the Central nervous system, stimulates the metabolism of norepinephrine and serotonin in brain tissues. Reduces platelet aggregation, blood viscosity, improves the deformability of red blood cells and normalization of venous outflow while reducing resistance of cerebral vessels. Systemic blood pressure decreases slightly. Efficacy in acute stroke: accelerates regression of cerebral and focal neurological symptoms, improves memory, attention, intellectual productivity. In the elderly and senile age, the sensitivity of cerebral vessels to the relaxing effect of Vinpocetine increases, due to the sensitization of the adenylate cyclase system-cyclic adenosine monophosphate in aging.

Indications:

• acute and chronic forms of cerebral circulation insufficiency (transient ischemic attacks, acute and residual stages of stroke, encephalopathy),
  
• mental and neurological disorders associated with cerebrovascular insufficiency (memory disorders, dizziness, headache, aphasia, apraxia, motor disorders),
  
• in ophthalmology: vascular diseases of the retina and / or choroid of the eye, degenerative changes of the macula caused by atherosclerosis or angiospasm, partial occlusion of blood vessels, secondary glaucoma,
  
• in otolaryngology: with senile hearing loss, Meniere's disease, hearing impairment of vascular or toxic (including drug) Genesis, with dizziness of labyrinthine origin.
  

Contraindications

Hypersensitivity, severe ischemic heart disease, severe forms of cardiac arrhythmias, acute phase of hemorrhagic stroke, pregnancy and lactation.

Method of application and doses

Intravenous drip. 20 mg diluted in 250-400 ml infusion solution. With good tolerability, the dose of the drug for 3-4 days is increased to 1 mg/kg, treatment is continued for 10-14 days. After the end of the course of parenteral administration, go to oral administration of the drug. Before the abolition of the drug dose should be gradually reduced.

Side effect

Dizziness, feeling of heat, hyperemia of the skin, nausea. On the part of the cardiovascular system, there may be a transient decrease in blood pressure, tachycardia, extrasystole, an increase in the excitation time of the ventricles, thrombophlebitis at the site of administration.

Interaction with other drugs

Vinpocetine increases the risk of hemorrhagic complications during heparin therapy. Vinpocetine solution is not pharmaceutically compatible with heparin.

Storage conditions

List B. in a dry, protected from light and out of reach of children at a temperature not exceeding 25 °C.